AstraZeneca reports Voydeya granted regulatory approval in Japan

Voydeya has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, announced AstraZeneca. “It is indicated in Japan in combination with C5 inhibitor therapy when patients have had an insufficient response to such C5 inhibitors. Voydeya is a first-in-class, oral, Factor D inhibitor developed as add-on to proven standard-of-care Ultomiris or Soliris to address the needs of the subset of approximately 10-20% patients with PNH who experience clinically significant extravascular haemolysis while treated with a C5 inhibitor,” the company stated.